v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid‑in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balances (in shares) at Dec. 31, 2023   33,437,296      
Beginning balances at Dec. 31, 2023 $ 242,360 $ 3 $ 437,132 $ 195 $ (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   30,888      
Issuance of common stock upon exercise of stock options 206   206    
Vesting of early exercised options (in shares)   3,411      
Vesting of early exercised options 13   13    
Vesting of restricted stock units (in shares)   132,458      
Stock‑based compensation 3,733   3,733    
Other comprehensive income (loss) (441)     (441)  
Net (loss) income 23,496       23,496
Ending balances (in shares) at Mar. 31, 2024   33,604,053      
Ending balances at Mar. 31, 2024 269,367 $ 3 441,084 (246) (171,474)
Beginning balances (in shares) at Dec. 31, 2023   33,437,296      
Beginning balances at Dec. 31, 2023 242,360 $ 3 437,132 195 (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Other comprehensive income (loss) (524)        
Net (loss) income 78,527        
Ending balances (in shares) at Jun. 30, 2024   37,172,496      
Ending balances at Jun. 30, 2024 429,925 $ 4 546,693 (329) (116,443)
Beginning balances (in shares) at Dec. 31, 2023   33,437,296      
Beginning balances at Dec. 31, 2023 $ 242,360 $ 3 437,132 195 (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of early exercised options (in shares) 1,676        
Ending balances (in shares) at Dec. 31, 2024 37,574,538 37,574,538      
Ending balances at Dec. 31, 2024 $ 428,678 $ 4 558,061 (43) (129,344)
Beginning balances (in shares) at Mar. 31, 2024   33,604,053      
Beginning balances at Mar. 31, 2024 269,367 $ 3 441,084 (246) (171,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   166,155      
Issuance of common stock upon exercise of stock options 1,104   1,104    
Vesting of early exercised options (in shares)   3,411      
Vesting of early exercised options 13   13    
Vesting of restricted stock units (in shares)   11,490      
Purchase of common stock under the employee stock purchase plan (in shares)   20,384      
Purchase of common stock under the employee stock purchase plan 263   263    
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392 (in shares)   3,367,003      
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392 99,608 $ 1 99,607    
Stock‑based compensation 4,622   4,622    
Other comprehensive income (loss) (83)     (83)  
Net (loss) income 55,031       55,031
Ending balances (in shares) at Jun. 30, 2024   37,172,496      
Ending balances at Jun. 30, 2024 $ 429,925 $ 4 546,693 (329) (116,443)
Beginning balances (in shares) at Dec. 31, 2024 37,574,538 37,574,538      
Beginning balances at Dec. 31, 2024 $ 428,678 $ 4 558,061 (43) (129,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   40,984      
Issuance of common stock upon exercise of stock options 350   350    
Vesting of early exercised options (in shares)   1,676      
Vesting of early exercised options 14   14    
Vesting of restricted stock units (in shares)   325,085      
Stock‑based compensation 5,087   5,087    
Other comprehensive income (loss) 480     480  
Net (loss) income (17,349)       (17,349)
Ending balances (in shares) at Mar. 31, 2025   37,942,283      
Ending balances at Mar. 31, 2025 $ 417,260 $ 4 563,512 437 (146,693)
Beginning balances (in shares) at Dec. 31, 2024 37,574,538 37,574,538      
Beginning balances at Dec. 31, 2024 $ 428,678 $ 4 558,061 (43) (129,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 53,090        
Vesting of early exercised options (in shares) 0        
Other comprehensive income (loss) $ 443        
Net (loss) income $ (60,452)        
Ending balances (in shares) at Jun. 30, 2025 38,033,970 38,033,970      
Ending balances at Jun. 30, 2025 $ 379,505 $ 4 568,897 400 (189,796)
Beginning balances (in shares) at Mar. 31, 2025   37,942,283      
Beginning balances at Mar. 31, 2025 417,260 $ 4 563,512 437 (146,693)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   12,106      
Issuance of common stock upon exercise of stock options 20   20    
Vesting of restricted stock units (in shares)   29,163      
Purchase of common stock under the employee stock purchase plan (in shares)   50,418      
Purchase of common stock under the employee stock purchase plan 317   317    
Stock‑based compensation 5,048   5,048    
Other comprehensive income (loss) (37)     (37)  
Net (loss) income $ (43,103)       (43,103)
Ending balances (in shares) at Jun. 30, 2025 38,033,970 38,033,970      
Ending balances at Jun. 30, 2025 $ 379,505 $ 4 $ 568,897 $ 400 $ (189,796)